Therapeutics News and Research

RSS

Study on RNAi technology targeting neurodegenerative diseases

Sirna Therapeutics has announced the publication of preclinical studies evaluating RNA interference-based therapies for a class of inherited neurodegenerative diseases of the central nervous system (CNS) in the current issue of Nature Medicine.

16 Aug 2004

Finnish company discovers over 200 new genes

Finnish company Jurilab has announced the completion of a genome-wide scan in Acute Myocardial Infarction in the East Finland Founder Population.

12 Aug 2004

Important for physicians to identify patients at risk for hyperkalemia and implement corresponding measures when using ACE inhibitors

Some patients with hypertension or other cardiovascular diseases should be closely monitored in order to maintain safe potassium levels in the body when prescribed certain medications, counsels a nephrologist at UT Southwestern Medical Center at Dallas.

11 Aug 2004

Free licences of European patents on the hereditary breast cancer gene BRCA2

The Institute of Cancer Research and Cancer Research Technology Limited, the technology transfer company of the charity Cancer Research UK, today announced the availability of free licences of European patents on the hereditary breast cancer gene BRCA2 to publicly funded research laboratories and not-for-profit research laboratories.

11 Aug 2004

Bionomics BNO69 angiogenesis gene discovery published

Bionomics has announced that research conducted by Bionomics and its collaborators at the Hanson Centre of the Institute of Medical and Veterinary Science ("IMVS") in Adelaide, Australia, relating to Bionomics' proprietary angiogenesis drug target BNO69, has been published in the high ranking scientific journal Proceedings of the National Academy of Sciences USA (PNAS).

10 Aug 2004

Total global market for oligonucleotides is likely to grow from USD 340.0 million in 2003 to USD 776.0 million in 2010

Poised on the brink of phenomenal growth, the oligonucleotides market offers a plethora of opportunities to the enterprising investor. Recent analysis by Frost & Sullivan estimates that the total global market for oligonucleotides is likely to grow from USD 340.0 million in 2003 to USD 776.0 million in 2010.

9 Aug 2004

CV Therapeutics initiates approval-enabling trial of drug to treat chronic angina

CV Therapeutics has announced that it has initiated an approval-enabling study of Ranexa, which, if successful, could support approval of Ranexa for the treatment of chronic angina in a restricted patient population.

3 Aug 2004

Metabasis Therapeutics announces multi-center Phase 2 study to evaluate the orally administered antiviral compound remofovir mesylate

Metabasis Therapeutics has announced the initiation of a multi-center, multi- national Phase 2 study to evaluate the orally administered antiviral compound remofovir mesylate in chronic hepatitis B (HBV) infected patients.

3 Aug 2004

Recommendation against the use of chemotherapy sensitivity and resistance assays

A new technology assessment from the American Society of Clinical Oncology states that the use of chemotherapy sensitivity and resistance assays (CSRAs) to select chemotherapeutic agents for cancer patients should not be undertaken outside of the clinical trial setting.

3 Aug 2004

Identification of PIK3CA as an oncogene associated with brain cancers opens the door to new screening processes

Hotspots in two areas of a gene that encodes a specific signaling enzyme, or kinase, are vulnerable to a variety of mutations found in five types of brain cancers, according to a report published in the August 1 issue of the journal Cancer Research.

2 Aug 2004

New process that simplifies the production of proteins

F. William Studier, a biophysicist at the U.S. Department of Energy's Brookhaven National Laboratory, has won a 2004 R&D 100 award for developing a new process that simplifies the production of proteins in the widely used T7 gene expression system.

29 Jul 2004

Y's Therapeutics files for clinical trials in Europe for rheumatoid arthritis and asthma

Y's Therapeutics, a privately held biopharmaceutical company, said today it has submitted applications to the Ethics Committee and Ministry of Health (BfArM) in Germany to begin Phase II clinical trials for its two most advanced projects, YSIL6 for rheumatoid arthritis and YSTH2 for asthma.

26 Jul 2004

New DNA microarray to speed bone disease research

Velcura Therapeutics has announced the development of a custom Affymetrix GeneChip(R) array that aids the development of bone disease therapies by enabling researchers to follow global changes in gene expression during human bone formation.

23 Jul 2004

Cancer Research Technology grants exclusive license to Genentech to patent portfolio of an oncology target

Cancer Research Technology announced today that it has entered into a license agreement granting Genentech, Inc. exclusive worldwide rights to its patent portfolio covering an oncology target discovered in the Molecular Oncology Laboratory (Oxford) of Cancer Research UK.

21 Jul 2004

3M and MicroDose Technologies Inc. team up to bring advanced electronic dry powder inhaler to market

3M and MicroDose Technologies Inc., a privately held drug delivery company based in Monmouth Junction, N.J., announced today that the two companies have entered into an exclusive co-development and joint marketing agreement.

20 Jul 2004

Market research 'World RNAi Markets: Current and Future Outlook'

Gene silencing by RNAi has now been identified as a crucial technology for target validation and therapeutics. By targeting and interfering with messenger RNA (mRNA), RNAi technology blocks the expression of the proteins implicated in disease progression.

19 Jul 2004

Therapeutics News and Research

Study on RNAi technology targeting neurodegenerative diseases

Finnish company discovers over 200 new genes

Important for physicians to identify patients at risk for hyperkalemia and implement corresponding measures when using ACE inhibitors

Free licences of European patents on the hereditary breast cancer gene BRCA2

Bionomics BNO69 angiogenesis gene discovery published

Total global market for oligonucleotides is likely to grow from USD 340.0 million in 2003 to USD 776.0 million in 2010

CV Therapeutics initiates approval-enabling trial of drug to treat chronic angina

Metabasis Therapeutics announces multi-center Phase 2 study to evaluate the orally administered antiviral compound remofovir mesylate

Recommendation against the use of chemotherapy sensitivity and resistance assays

Identification of PIK3CA as an oncogene associated with brain cancers opens the door to new screening processes

New process that simplifies the production of proteins

Y's Therapeutics files for clinical trials in Europe for rheumatoid arthritis and asthma

New DNA microarray to speed bone disease research

Cancer Research Technology grants exclusive license to Genentech to patent portfolio of an oncology target

3M and MicroDose Technologies Inc. team up to bring advanced electronic dry powder inhaler to market

Market research 'World RNAi Markets: Current and Future Outlook'

Targeted therapeutics capable of preventing or limiting the metastasis of skin cancer

Strategic analysis of the breast cancer therapeutics pipeline

Cell Therapeutics receives Fast Track Designation for Pixantrone, treatment for aggressive non-Hodgkin's lymphoma

Myriad Genetics awarded a $14.2 million contract for AIDS and hepatitis research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News